Media

The Instagram era brought the culinary world a category of food that favors novelty and encourages hybrid combinations, of course we’re talking about viral food. People from around the world line up for blocks to get a taste, and more importantly a photo, of these photogenic foods, because obviously “pics or it didn’t happen.” We’re talking over-the-top milkshakes, gold Cristal donuts, and who can forget the rainbow bagel. Since this Instagrub sensation doesn’t seem to be slowing down anytime soon, we scoured the city for the next crop of Instafamous foods. So grab your Instagram husband because in this edition of the NYC Urban Guidebook we’re skipping the two hour wait at Black Tap and passing by Dominique Ansel as host Annamaria Stewart (@annamaria_stewart) presents our picks for food porn – The New Class.

1) Vivi Bubble Tea LES (@vivibubbleteales) – Cotton Candy Bubble Tea Float

2) Clinton Hall (@clintonhallny) – Walter White Crystal Methadonuts

3) Cupcake Market (@cupcakemarketnyc) – Candidate Cookies / Kim, Kanye and Taylor Cookies

4) Cha Cha Matcha (@chachamatcha) – Matcha Latte Foam Portraits

5) Stick With Me Sweets (@swmsweets) – Storybook Bonbons

6) by CHLOE (@bychefchloe) – Chic Vegan Eats

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

New York is home to some of the most famous art museums in the world, but stepping outside these museum walls opens you up to one of the globe’s largest street art collections. With so much to take in, you’ll need a guide to find the best the city has to offer. Host Annamaria Stewart (@annamariachen) heads to the Bushwick Collective (@TheBKCollective) to meet up with Gabe Schoenberg, an expert on the New York street art and graffiti scene and the owner of Graff Tours (@GraffTours), New York’s first tour dedicated to urban art.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

JERUSALEM, June 21, 2016 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone payment from the previously-announced license and investment agreement between Oramed and HTIT. The payment follows Oramed’s positive top-line results from its Phase IIb U.S. Food and Drug Administration trial designed to evaluate the safety and efficacy of Oramed’s oral insulin capsule ORMD-0801 in patients with type 2 diabetes.

Per the terms of the agreement signed in December 2015, Oramed granted HTIT exclusive rights for commercialization of ORMD-0801 in Greater China. The up to $50 million license deal includes multiple milestone payments aggregating $38 million, with a $3 million upfront payment received by Oramed upon execution of the agreement, plus a $12 million investment made by HTIT in Oramed at $10.39 per share in December 2015. Oramed will receive a 10% royalty on net sales of ORMD-0801 and related commercialized products in Greater China.

“The completion of this milestone signifies our deepening partnership with HTIT as we move closer to bringing oral insulin to the vast and growing Chinese diabetes market,” said Nadav Kidron, CEO of Oramed.

“The positive Phase IIb data has further illustrated the huge potential this technology can have in China,” said HTIT CFO & Oramed Board Member Xiaopeng Li. “We are working diligently to lay the groundwork for the successful production and commercialization of ORMD-0801 focused on the Greater China market.”

About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

JACKSONVILLE, Florida, June 21, 2016 /PRNewswire/ —

TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced reaching a major milestone of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200. The first patient enrolled is being treated at the University of Maryland – one of 8 sites being used in this study, conducted and funded by TapImmune.

The randomized, open label Phase 2 study is expected to enroll a total of 80 subjects. The primary endpoints are dosing regimens and safety. Secondary endpoints are T-cell specific responses and evaluation of objective responses.

Dr. Glynn Wilson, Chairman and CEO of Tapimmune stated, “Enrolling and treating this first patient represents the start of a robust and intensive Phase 2 clinical program for our lead product TPIV 200, a Folate Receptor Alpha T-cell vaccine.”

TPIV 200 is currently being investigated in two other Phase 2 trials at the Mayo Clinic and at Memorial Sloan Kettering.

“Enrollment has started in the Phase 2 40 patient study at Memorial Sloan Kettering in collaboration with Astra Zeneca in late-stage ovarian cancer. In addition, the large 280 patient Phase 2 trial being run at the Mayo Clinic with a grant from the Department of Defense is expected to start enrollment later this year,” Dr. Wilson added.

TapImmune has received Fast Track Status and Orphan Drug Designation for TPIV 200. The Company plans to initiate a fourth Phase 2 clinical study, in late 2016, designed to treat platinum-sensitive ovarian cancer patients.

“The clinical strategy for TPIV 200 is designed to examine the potential for this exciting T-cell vaccine in as many clinical settings as possible using the most cost-effective pathways. We are excited by the potential for this drug candidate and believe positive data from the Phase 1 study will be reflected in the results of our ongoing Phase 2 clinical investigations,” Dr. Wilson concluded.

Interested investors in TapImmune’s clinical studies can learn more by going to: http://www.clinicaltrials.gov

TEL-AVIV, June 24, 2016 /PRNewswire/ — Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced newly available data from its successfully completed Phase III study of KIT-302 suggest beneficial effects on kidney(renal) function. Damage to renal function is a serious side effect of NSAIDs.

The Company’s combination drug, KIT-302, simultaneously treats pain caused by osteoarthritis and treats hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain. KIT-302 is comprised of two U.S. Food and Drug Administration approved drugs, celecoxib (Celebrex®) for the treatment of pain caused by osteoarthritis and amlodipine besylate, a drug designed to treat hypertension.

Further analysis of data obtained in the Phase III clinical trial, whose top line results were announced in December 2015,showed that celecoxib increased serum creatinine compared to placebo;impaired renal function is a major concern with nonsteroidal anti-inflammatory drugs (NSAIDs). In contrast, while amlodipine alone reduced serum creatinine (-2.55 umol/L), a greater reduction in plasma levels of creatinine was achieved in patients in the KIT-302 arm (-3.22 umol/L), suggesting better renal function.

Additional data supporting the conclusion that KIT-302 is beneficial to renal function were measurements of peripheral edema, a known side effect of calcium channel blockers, such as amlodipine. Peripheral edema was reported in 15.6% of patients receiving amlodipine but in only 8.2% of patients receiving KIT-302. These data suggest that KIT-302 protects against the widely recognized undesirable side effect of amlodipine in causing fluid retention by the kidneys.

Dr. Paul Waymack, Kitov’s Chief Medical Officer,said: “We are very pleased with the outcome of the renal function analysis. We believe it demonstrates that in addition to addressing hypertension side effects caused by celecoxib, KIT-302 also addresses fluid retention resulting from amlodipine: a known side effect caused by calcium channel blockers.”

“Given the potential marketing advantages of these findings,we intend to conduct a clinical trial designed to scientifically validate these beneficial renal effects in parallel with the New Drug Application we plan to submit at the end of 2016,” stated Chief Executive Officer Isaac Israel. The study may also provide an explanation for the synergistic antihypertensive effect, where the reduction in blood pressure demonstrated with KIT-302 was higher than that observed with amlodipine alone.”

HAIFA, Israel, June 22, 2016 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI), (PSTI)/(PLTR), a leading developer of placenta-based cell therapy products, today reported positive data from preclinical studies of its PLX-PAD cells in the treatment of Duchenne muscular dystrophy. The studies were conducted in conjunction with ADI, the Association Duchenne Israel, whose members are parents of children with Duchenne. They are committed to helping to find a cure for Duchenne muscular dystrophy through research, clinical trials, and advocacy.

Duchenne muscular dystrophy is the most common neuromuscular disorder, and affects roughly one in 3,500 boys. The disease causes progressive muscle weakness, and leads to severe disability and death. There is currently no cure.

Following Pluristem’s announcement of positive results from a Phase II clinical trial of PLX-PAD as a treatment for muscle injury, the Association Duchenne Israel approached Pluristem with a request to study PLX-PAD cells in Duchenne muscular dystrophy. Pluristem donated PLX-PAD cells for the preclinical studies, and the association supported the research in cooperation with Science in Action Ltd.

The studies demonstrated that, in a mouse model of muscular dystrophy, PLX-PAD cells reduced creatine phosphokinase (CPK), a marker of muscle degeneration or injury, by approximately 50% as compared to placebo. CPK levels were measured via a blood sample taken 5 days after each intramuscular PLX-PAD injection made at day 15 and day 29 of the study. Histological analyses of quadriceps and diaphragm muscles show PLX-PAD reduced levels of inflammation and necrosis, a type of cell death, and induced regeneration of muscle tissue.

Hila Krupsky, CEO of ADI, the Association Duchenne Israel, stated, “These preclinical data suggest that PLX-PAD cells could possibly be a breakthrough therapy to help treat symptoms of Duchenne muscular dystrophy. We are thankful for Pluristem’s donation of PLX-PAD and are eager to continue studying the cells since new therapeutic approaches are needed to manage this disease, save children’s lives, and give them hope and a chance for the future.”

“Because PLX-PAD cells have already displayed efficacy in muscle regeneration in a Phase II muscle injury study, we believe our cell therapy may potentially be beneficial in Duchenne muscular dystrophy in human clinical trials,” said Pluristem Chairman and CEO Zami Aberman. “We admire the commitment of the Association Duchenne Israel to find a cure for Duchenne muscular dystrophy, and we will work closely with them in an effort to develop a treatment for the children around the world who suffer from this disease.”

PETACH TIKVA, Israel, June 15, 2016 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced new mechanism of action data indicating its lead drug candidate, Piclidenoson (CF101) inhibits two inflammatory cytokines, interleukin 17 (IL-17) and interleukin 23 (IL-23) which are known to play a major role in the inflammatory process of psoriasis.

Biologic drugs, which are injectable immunomodulators, for the treatment of psoriasis currently on the market and in development, also work via a similar mechanism of action by inhibiting IL-17 and IL-23. These systemic drugs offer good efficacy, however, as biologics they can cause serious side effects.

Piclidenoson binds to the Gi protein associated A3 adenosine receptor (A3AR), which is over- expressed in psoriasis patients. This binding action has shown to induce a robust anti-inflammatory effect by inhibiting IL-17 and IL-23 as demonstrated in in-vitro studies. An orally administered small molecule drug, Piclidenoson, potentially offers safety superior to biologics as shown in clinical studies in approximately 1,000 people.
These findings will be presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network, in Paris, France on July 7, 2016. The oral presentation titled, “CF101 via A3AR Activation inhibits IL-17 and IL-23” is scheduled for 10:10 am during the Late Breaking News Session.

“We believe that the discovery of this new mechanistic pathway of Piclidenoson will position it as a strong drug candidate to treat psoriasis with potential efficacy similar to biologics on the market today, while potentially offering superior safety as a small molecule oral drug,” stated Can-Fite CEO, Dr. Pnina Fishman.

The global psoriasis market is estimated to reach $9 billion by 2018 (Visiongain). Can-Fite recently announced the submission of its Phase III protocol design to the European Medicines Agency for Piclidenoson in the treatment of psoriasis and expects to commence the trial in 2016.

It might only cost two bucks to pony up but it took over 15 million dollars and 27 years to bring a 1922 Carousel from Youngstown, Ohio to a clear pavilion in Brooklyn Bridge Park. Host Annamaria Stewart (@annamariachen) meets up with Jane Walentas, the woman behind Jane’s Carousel (@janescarousel), to learn the storied past of Brooklyn’s iconic Carousel.

www.JanesCarousel.com

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

If you’ve ever been to Hong Kong you are undoubtedly familiar with the city’s most popular street food, egg waffles. Since this Cantonese street snack landed stateside it has been a fixture in Chinatowns across the country, but has mostly remained a well-kept secret amongst neighborhood locals. This year Mulberry Street received a new addition, Eggloo (@myeggloo), which is bringing egg waffles to the masses with a hybrid twist that proves everything is better with ice cream. Host Annamaria Stewart (@annamariachen) meets up with Eggloo co-founder Mike Tan to learn more about New York’s latest viral food craze.

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

In the late 1800’s Italians immigrated to the United States via New York’s own Ellis Island, bringing with them a recipe for something called Pizza. In 1905 America’s first pizzeria was opened on Spring Street in Little Italy. With so much history it’s no surprise that New York City still churns out some of the most authentic pizza pies in North America. So if you want the country’s best pizza, you come to New York and if you want to learn how to make it, you come to Pizza a Casa pizza school on the Lower East Side. Host Annamaria Stewart (@AnnamariaChen) sits down with owner Mark Bello to learn about the history of Pizza a Casa and partakes in their pizza self-sufficiency class, tackling a classic Neapolitan pizza while Mark demonstrates how to make the perfect New York style pie, giving viewers a preview of how to make restaurant quality pizza in their home kitchen.

Pizza a Casa Pizza School – www.pizzaschool.com

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

Music : Bushwick Tarantella by Kevin MacLeod is licensed under a Creative Commons Attribution license (https://creativecommons.org/licenses/…)
Source: http://incompetech.com/music/royalty-…
Artist: http://incompetech.com/